Erlotinib Hydrochloride Novel Drug Delivery Systems: A mini review unravelling the role of micro- and nanocarriers

2021 ◽  
Vol 11 ◽  
Author(s):  
Chaitali Taiwade ◽  
Aditi Fulfager ◽  
Hardik Bhargave ◽  
Govind Soni Soni ◽  
Khushwant Yadav
Keyword(s):  
Drug Delivery ◽  
Oral Delivery ◽  
Drug Delivery Systems ◽  
Kinase Inhibitor ◽  
Therapeutic Potential ◽  
Metastatic Cancer ◽  
Locally Advanced ◽  
Delivery Systems ◽  
Advanced Lung Cancer ◽  
Medication Delivery

: Erlotinib is a tyrosine kinase inhibitor and it can treat tumors, such as pancreatic and locally advanced lung cancer or metastatic cancer. The traditional formulation of erlotinib currently available is an oral delivery type that presents serious side effects such as hepatotoxicity, skin rashes, gastrointestinal disturbance, renal dysfunction, drug resistance and hematological symptoms. Besides this, other disadvantages of erlotinib provided mostly by oral administration are the comprehensive metabolism, low bioavailability, poor solubility and off-target impact. Overcoming such unfavorable attributes of the medication, innovative medication delivery mechanisms like nanocapsules, liposomes, microspheres, microparticles solid lipid nanoparticles, nanosponge, and nanoparticles have been studied that have really shown their lead over traditional formulations. This article summarizes the novel erlotinib drug delivery systems to boost its clinical efficacy and reduce systemic toxicity. Novel formulations of erlotinib will offer positive outcomes in cancer therapy and will play an important part in improving the drug's therapeutic potential.

scholarly journals Therapeutic potential of exosomes and their derivatives

2018 ◽  
pp. 129-131
Author(s):  
И.Ю. Малышев ◽  
Л.В. Кузнецова ◽  
О.П. Буданова
Keyword(s):  
Drug Delivery ◽  
Immune System ◽  
Drug Delivery Systems ◽  
Therapeutic Potential ◽  
Delivery Systems ◽  
Current Data ◽  
Natural Origin ◽  
Advantages And Disadvantages ◽  
Efficient Delivery ◽  
Synthetic Drug

В обзоре представлены современные данные о механизмах диагностики, планирования и оценки успешности терапии различных заболеваний с помощью экзосом, об использовании их как нанопереносчиков (т.е. нановезикул для эффективной доставки молекул). За последние годы разработано большое количество разных, в основном синтетических, систем доставки лекарственных средств, недостатками этих систем является плохая биосовместимость и органическая неспособность к высокоточной доставке загруженных веществ. По сравнению с синтетическими системами доставки лекарственных средств, экзосомы - вследствие своего естественного происхождения - могут обладать большими преимуществами, такими, как лучшая биосовместимость и повышенная устойчивость к разрушительному воздействию иммунной системы. Описана технология производства наноструктур, разработка и производство с помощью бионанотехнологий так называемых «полностью синтетических экзосомоподобных нановезикул», преимущества и недостатки этих методов. This review presents current data on mechanisms for diagnosis, planning, and evaluation of success in the treatment of various diseases using exosomes as nanocarriers (i.e., nanovesicles for efficient delivery of molecules). In recent years, a large number of different, mainly synthetic drug delivery systems has been developed. Disadvantages of these systems are poor biocompatibility and organic inability to deliver high-precision loaded substances. Compared with synthetic drug delivery systems, exosomes due to their natural origin may provide great advantages, such as better biocompatibility and increased resistance to detrimental effects of the immune system. This review describes in detail a technology of nanostructure production, the development and production of so-called fully synthetic exosome-like nanovesicles using bionanotechnology, and advantages and disadvantages of these methods.

Review on Nanotechnology and its utilization in Pharmaceuticals

2021 ◽  
pp. 319-322
Author(s):  
Kiran Patole ◽  
Anil Danane ◽  
Amit Nikam ◽  
Anuja Patil
Keyword(s):  
Drug Delivery ◽  
Pharmaceutical Industry ◽  
Molecular Biology ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Medication Delivery ◽  
Traditional Drug ◽  
Pharmaceutical Nanotechnology

Nanotechnology is the study of tiny structures ranging in size from 0.1 to 100 nanometers. It includes biophysics, molecular biology, and bioengineering, as well as medical subspecialties such as cardiology, ophthalmology, endocrinology, oncology, and immunology. Pharmaceutical Nanotechnology combines the methods and ideas of nanoscience and nanomedicine with pharmacy to create novel medication delivery systems that transcend the limitations of traditional drug delivery systems. The purpose of this article is to provide an overview of nanotechnology and its uses in the pharmaceutical industry.

Nanoparticles with surface features of dendritic oligopeptides as potential oral drug delivery systems

2020 ◽  
Vol 8 (13) ◽  
pp. 2636-2649
Author(s):  
Yuli Bai ◽  
Rui Zhou ◽  
Lei Wu ◽  
Yaxian Zheng ◽  
Xi Liu ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Specific Surface ◽  
Oral Delivery ◽  
Drug Delivery Systems ◽  
Oral Drug Delivery ◽  
Delivery Systems ◽  
Oral Drug ◽  
Protein Drugs ◽  
Surface Features ◽  
Oral Drug Delivery Systems

Endowing the NPs with specific surface features of dendritic oligopeptides holds great potential for the oral delivery of peptide/protein drugs.

Paliperidone-Loaded Self-Emulsifying Drug Delivery Systems (SEDDS) for Improved Oral Delivery

2012 ◽  
Vol 33 (4) ◽  
pp. 506-515 ◽  
Author(s):  
Swetha Kanuganti ◽  
Raju Jukanti ◽  
Prabhakar R. Veerareddy ◽  
Suresh Bandari
Keyword(s):  
Drug Delivery ◽  
Oral Delivery ◽  
Drug Delivery Systems ◽  
Delivery Systems

scholarly journals A Review on Chitosan’s Uses as Biomaterial: Tissue Engineering, Drug Delivery Systems and Cancer Treatment

Materials ◽  
2020 ◽  
Vol 13 (21) ◽  
pp. 4995 ◽  
Author(s):  
Rayssa de Sousa Victor ◽  
Adillys Marcelo da Cunha Santos ◽  
Bianca Viana de Sousa ◽  
Gelmires de Araújo Neves ◽  
Lisiane Navarro de Lima Santana ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Tissue Engineering ◽  
Metal Ions ◽  
Cancer Treatment ◽  
Drug Delivery Systems ◽  
Therapeutic Potential ◽  
Delivery Systems ◽  
Amino Groups ◽  
New Information ◽  
Acidic Conditions

Chitosan, derived from chitin, is a biopolymer consisting of arbitrarily distributed β-(1-4)-linked D-glucosamine and N-acetyl-D-glucosamine that exhibits outstanding properties— biocompatibility, biodegradability, non-toxicity, antibacterial activity, the capacity to form films, and chelating of metal ions. Most of these peculiar properties are attributed to the presence of free protonable amino groups along the chitosan backbone, which also gives it solubility in acidic conditions. Moreover, this biopolymer can also be physically modified, thereby presenting a variety of forms to be developed. Consequently, this polysaccharide is used in various fields, such as tissue engineering, drug delivery systems, and cancer treatment. In this sense, this review aims to gather the state-of-the-art concerning this polysaccharide when used as a biomaterial, providing information about its characteristics, chemical modifications, and applications. We present the most relevant and new information about this polysaccharide-based biomaterial’s applications in distinct fields and also the ability of chitosan and its various derivatives to selectively permeate through the cancer cell membranes and exhibit anticancer activity, and the possibility of adding several therapeutic metal ions as a strategy to improve the therapeutic potential of this polymer.

scholarly journals Inflammatory Bowel Disease: The Emergence of New Trends in Lifestyle and Nanomedicine as the Modern Tool for Pharmacotherapy

Nanomaterials ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. 2460
Author(s):  
Eden Mariam Jacob ◽  
Ankita Borah ◽  
Sindhu C Pillai ◽  
D. Sakthi Kumar
Keyword(s):  
Drug Delivery ◽  
Inflammatory Bowel Disease ◽  
Immune System ◽  
Bowel Disease ◽  
Oral Delivery ◽  
Drug Delivery Systems ◽  
Genetic Defect ◽  
Delivery Systems ◽  
Conventional Drug ◽  
Inflammatory Bowel

The human intestine, which harbors trillions of symbiotic microorganisms, may enter into dysbiosis when exposed to a genetic defect or environmental stress. The naissance of chronic inflammation due to the battle of the immune system with the trespassing gut bacteria leads to the rise of inflammatory bowel disease (IBD). Though the genes behind the scenes and their link to the disease are still unclear, the onset of IBD occurs in young adults and has expanded from the Western world into the newly industrialized countries. Conventional drug deliveries depend on a daily heavy dosage of immune suppressants or anti-inflammatory drugs targeted for the treatment of two types of IBD, ulcerative colitis (UC) and Crohn’s disease (CD), which are often associated with systemic side effects and adverse toxicities. Advances in oral delivery through nanotechnology seek remedies to overcome the drawbacks of these conventional drug delivery systems through improved drug encapsulation and targeted delivery. In this review, we discuss the association of genetic factors, the immune system, the gut microbiome, and environmental factors like diet in the pathogenesis of IBD. We also review the various physiological concerns required for oral delivery to the gastrointestinal tract (GIT) and new strategies in nanotechnology-derived, colon-targeting drug delivery systems.

scholarly journals Myristic Acid Coated Protein Immobilised Mesoporous Silica Particles as pH Induced Oral Delivery System for the Delivery of Biomolecules

2019 ◽  
Vol 12 (4) ◽  
pp. 153
Author(s):  
Vivek Trivedi ◽  
Ruchir Bhomia ◽  
John C Mitchell
Keyword(s):  
Drug Delivery ◽  
Mesoporous Silica ◽  
Protein Conformation ◽  
Myristic Acid ◽  
Oral Delivery ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Silica Particles ◽  
Protein Release ◽  
Simulated Gastric Fluid

Solid core drug delivery systems (SCDDS) were prepared for the oral delivery of biomolecules using mesoporous silica as core, bovine haemoglobin (bHb) as model drug and supercritical fluid (SCF) processing as encapsulation technique. The use of organic solvents or harsh processing conditions in the development of drug delivery systems for biomolecules can be detrimental for the structural integrity of the molecule. Hence, the coating on protein-immobilised particles was performed via supercritical carbon dioxide (scCO2) processing at a temperature lower than the melting point of myristic acid (MA) to avoid any thermal degradation of bHb. The SCDDS were prepared by bHb immobilisation on mesoporous silica followed by myristic acid (MA) coating at 43 °C and 100 bar in scCO2. bHb-immobilised silica particles were also coated via solvent evaporation (SE) to compare the protein release with scCO2 processed formulations. In both cases, MA coating provided required enteric protection and restricted the bHb release for the first two hours in simulated gastric fluid (SGF). The protein release was immediate upon the change of media to simulated intestinal fluid (SIF), reaching 70% within three hours. The release from SCF processed samples was slower than SE formulations, indicating superior surface coverage of MA on particles in comparison to the SE method. Most importantly, the protein conformation remained unchanged after the release from SCDDS as confirmed by circular dichroism. This study clearly demonstrates that the approach involving protein immobilisation on silica and scCO2 assisted melt-coating method can protect biomolecules from gastric environment and provide the required release of a biologic in intestine without any untoward effects on protein conformation during processing or after release.

Sign in / Sign up

Export Citation Format

Share Document